RU2018136750A3 - - Google Patents

Download PDF

Info

Publication number
RU2018136750A3
RU2018136750A3 RU2018136750A RU2018136750A RU2018136750A3 RU 2018136750 A3 RU2018136750 A3 RU 2018136750A3 RU 2018136750 A RU2018136750 A RU 2018136750A RU 2018136750 A RU2018136750 A RU 2018136750A RU 2018136750 A3 RU2018136750 A3 RU 2018136750A3
Authority
RU
Russia
Application number
RU2018136750A
Other languages
Russian (ru)
Other versions
RU2778514C2 (ru
RU2018136750A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54834568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2018136750(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of RU2018136750A publication Critical patent/RU2018136750A/ru
Publication of RU2018136750A3 publication Critical patent/RU2018136750A3/ru
Application granted granted Critical
Publication of RU2778514C2 publication Critical patent/RU2778514C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018136750A 2014-06-12 2015-06-12 Модуляция активности комплемента RU2778514C2 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462011368P 2014-06-12 2014-06-12
US62/011,368 2014-06-12
US201462077460P 2014-11-10 2014-11-10
US62/077,460 2014-11-10
US201562108772P 2015-01-28 2015-01-28
US62/108,772 2015-01-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2016147080A Division RU2670988C2 (ru) 2014-06-12 2015-06-12 Модуляция активности комплемента

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2022116223A Division RU2022116223A (ru) 2014-06-12 2022-06-16 Модуляция активности комплемента

Publications (3)

Publication Number Publication Date
RU2018136750A RU2018136750A (ru) 2018-11-06
RU2018136750A3 true RU2018136750A3 (cg-RX-API-DMAC7.html) 2021-10-19
RU2778514C2 RU2778514C2 (ru) 2022-08-22

Family

ID=

Also Published As

Publication number Publication date
IL273746B (en) 2021-03-25
AU2019200828B2 (en) 2021-04-08
LUC00343I2 (cg-RX-API-DMAC7.html) 2026-05-05
US20210246167A1 (en) 2021-08-12
KR20190057420A (ko) 2019-05-28
US10562934B2 (en) 2020-02-18
AU2021204313B2 (en) 2024-01-04
SMT201900568T1 (it) 2019-11-13
JP7454545B2 (ja) 2024-03-22
CY1124595T1 (el) 2022-07-22
BR112016029076B1 (pt) 2024-02-15
IL273746A (en) 2020-05-31
AU2015274482B2 (en) 2018-11-08
CA2949985C (en) 2023-10-17
MX2021009309A (es) 2021-10-26
DK3628680T3 (da) 2021-10-11
ES2895029T3 (es) 2022-02-17
MX2016016449A (es) 2017-08-24
RU2670988C2 (ru) 2018-10-29
RS59353B1 (sr) 2019-10-31
WO2015191951A2 (en) 2015-12-17
KR20220002727A (ko) 2022-01-06
BR122023024819A2 (pt) 2023-12-26
LT3154561T (lt) 2019-11-25
ZA202001859B (en) 2021-04-28
CY2024015I2 (el) 2024-12-13
CA3174909A1 (en) 2015-12-17
KR102503319B1 (ko) 2023-02-28
HRP20191763T1 (hr) 2019-12-27
CN111187338B (zh) 2024-08-02
US20180371019A1 (en) 2018-12-27
PL3628680T3 (pl) 2022-01-10
RS62428B1 (sr) 2021-11-30
JP7002597B2 (ja) 2022-02-04
ES2750556T3 (es) 2020-03-26
EP4223317A3 (en) 2023-09-27
FR24C1022I2 (fr) 2025-05-23
WO2015191951A3 (en) 2016-03-03
US20200002380A1 (en) 2020-01-02
US20170137468A1 (en) 2017-05-18
AU2021204313A1 (en) 2021-07-22
EP3154561A2 (en) 2017-04-19
AP2016009612A0 (en) 2016-12-31
US11965040B2 (en) 2024-04-23
CY1122227T1 (el) 2020-11-25
HRP20211561T8 (hr) 2022-03-04
US11535650B1 (en) 2022-12-27
US10435438B2 (en) 2019-10-08
SI3154561T1 (sl) 2019-11-29
IL281264A (en) 2021-04-29
CN106456701A (zh) 2017-02-22
PT3628680T (pt) 2021-10-07
CN106456701B (zh) 2020-01-07
LT3628680T (lt) 2021-11-25
PL3154561T3 (pl) 2019-12-31
BR112016029076A2 (pt) 2018-06-05
US20190119328A1 (en) 2019-04-25
ZA201900497B (en) 2019-10-30
BR112016029076A8 (pt) 2022-02-08
JP2019048834A (ja) 2019-03-28
RU2016147080A3 (cg-RX-API-DMAC7.html) 2018-06-01
EP3154561A4 (en) 2018-04-18
ZA201706379B (en) 2018-12-19
FR24C1022I1 (fr) 2024-07-19
CA2949985A1 (en) 2015-12-17
US11014965B2 (en) 2021-05-25
LTPA2024514I1 (cg-RX-API-DMAC7.html) 2024-06-10
CY2024015I1 (el) 2024-12-13
NO2024023I1 (no) 2024-05-24
JP6432954B2 (ja) 2018-12-05
EP3154561B1 (en) 2019-09-04
EP3973994A1 (en) 2022-03-30
LUC00343I1 (cg-RX-API-DMAC7.html) 2024-05-16
JP2017523232A (ja) 2017-08-17
AU2019200828A1 (en) 2019-02-28
IL249093A0 (en) 2017-01-31
CN119236050A (zh) 2025-01-03
PT3154561T (pt) 2019-10-25
US10106579B2 (en) 2018-10-23
KR102346228B1 (ko) 2022-01-04
NZ727420A (en) 2018-06-29
EP3628680B1 (en) 2021-09-08
JP2020128417A (ja) 2020-08-27
NZ761610A (en) 2024-03-22
SG11201610222UA (en) 2017-01-27
HUE045646T2 (hu) 2020-01-28
SI3628680T1 (sl) 2021-12-31
AU2015274482A1 (en) 2017-01-12
DK3154561T3 (da) 2019-10-07
RU2016147080A (ru) 2018-06-01
US10208089B2 (en) 2019-02-19
BR122021025449B1 (pt) 2024-02-15
NL301275I2 (nl) 2024-06-20
KR20170003993A (ko) 2017-01-10
HUE055931T2 (hu) 2022-01-28
CA3313802A1 (en) 2026-06-21
US20200123202A1 (en) 2020-04-23
EP4223317A2 (en) 2023-08-09
CA3241273A1 (en) 2015-12-17
EP3628680A1 (en) 2020-04-01
HUS2400015I1 (hu) 2024-06-28
JP6770043B2 (ja) 2020-10-14
LTC3154561I2 (cg-RX-API-DMAC7.html) 2025-11-10
NZ736573A (en) 2024-03-22
SMT202100588T1 (it) 2021-11-12
CN111187338A (zh) 2020-05-22
IL249093B (en) 2020-05-31
HRP20211561T1 (hr) 2021-12-24
JP2022034057A (ja) 2022-03-02
FIC20240015I1 (fi) 2024-05-28
IL281264B (en) 2022-05-01
RU2018136750A (ru) 2018-11-06
KR101981532B1 (ko) 2019-09-02

Similar Documents

Publication Publication Date Title
BR112016017664A2 (cg-RX-API-DMAC7.html)
BR112016016761A2 (cg-RX-API-DMAC7.html)
BR112016015519A2 (cg-RX-API-DMAC7.html)
BR112016015890A2 (cg-RX-API-DMAC7.html)
BR112016016490A2 (cg-RX-API-DMAC7.html)
BR112016016546A2 (cg-RX-API-DMAC7.html)
BR112016014949A2 (cg-RX-API-DMAC7.html)
BR112016017103A2 (cg-RX-API-DMAC7.html)
BR112016016612A2 (cg-RX-API-DMAC7.html)
BR112016016924A2 (cg-RX-API-DMAC7.html)
BR112016016421A2 (cg-RX-API-DMAC7.html)
BR112016016106A2 (cg-RX-API-DMAC7.html)
BR112016012568A2 (cg-RX-API-DMAC7.html)
BR112016016558A2 (cg-RX-API-DMAC7.html)
BR112016017960A2 (cg-RX-API-DMAC7.html)
BR112016015915A2 (cg-RX-API-DMAC7.html)
BR112016017216A2 (cg-RX-API-DMAC7.html)
BR112016016389A2 (cg-RX-API-DMAC7.html)
BR112016016468A2 (cg-RX-API-DMAC7.html)
BR112016017356A2 (cg-RX-API-DMAC7.html)
BR112016016459A2 (cg-RX-API-DMAC7.html)
BR112016015963A2 (cg-RX-API-DMAC7.html)
BR112016003522A2 (cg-RX-API-DMAC7.html)
BR112016014482A2 (cg-RX-API-DMAC7.html)
BR112016015054A2 (cg-RX-API-DMAC7.html)